The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In this video, which is part of an educational series on myelodysplastic syndromes with SOHO young investigators, Rami Komrokji, MD, leads a discussion on risk stratification and clinical decision-making in MDS, including the use of IPSS-R and IPSS-M, treatment strategies and the timing of stem cell transplantation.
Host Dr. Loretta Nastoupil also discusses with Dr. Xavier how to navigate second-line regimens like monoclonal antibodies versus bispecific T-cell engagers and manage logistical and toxicity concerns in community settings.
“This chemotherapy-blinatumomab risk-oriented program yielded remarkable results that need further improvement in higher-risk patients displaying early MRD persistence,” wrote the study’s authors, led by Renato Bassan, MD, of Ospedale dell’Angelo in Venice, Italy.
The study’s authors, led by Marin Schrappe, MD, of Christian Albrechts University Kiel and University Hospital Schleswig-Holstein in Germany, enrolled pediatric patients with high-risk B-ALL to receive two cycles of either blinatumomab or control chemotherapy after consolidation therapy. The primary end point was EFS based on a time-to-event analysis.
The combination of iberdomide, a novel cereblon E3 ligase modulator, with daratumumab and dexamethasone improved rates of minimal residual disease–negative complete response compared with daratumumab,
Offering practical advice for community physicians on managing toxicities while maintaining efficacy, Dr. Nooka explained how to modify standard schedules.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
